Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297017 | 0.93 | KMT2A (0.45) | ALDH1A1KMT2AMEN1LMNAHTT | |
| SCHEMBL4292291 | 0.88 | KMT2A (0.42) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4291080 | 0.87 | KMT2A (0.40) | KMT2AMEN1 | |
| SCHEMBL4287492 | 0.87 | MEN1 (0.41) | KMT2AMEN1 | |
| SCHEMBL4296392 | 0.86 | MEN1 (0.42) | KMT2AMEN1 | |
| SCHEMBL4296733 | 0.85 | MEN1 (0.40) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4295874 | 0.85 | MEN1 (0.44) | KMT2AMEN1 | |
| SCHEMBL4293980 | 0.84 | MEN1 (0.44) | KMT2AMEN1 | |
| SCHEMBL4287067 | 0.83 | MEN1 (0.48) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4288838 | 0.83 | MEN1 (0.42) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | BONFANTI JEAN-FRANCOIS | 2009-09-03 | — | — | US | disclosed |
| WO-2007026024-A2 | BENZODIAZEPINES AS HCV INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221559-A1 | BENZODIAZEPINES AS HCV INHIBITORS | GABRA5, GABRA4, GABRA3 | NTRK1 3822/4885F10 3396/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.